Weight Loss

Semaglutide vs Tirzepatide: Comparing GLP-1 Options for Women

April 2026 · 5 min read

Semaglutide and tirzepatide are the two most-prescribed medications in the GLP-1 class, and they're often discussed as if they were interchangeable. They're not. Understanding what distinguishes them — in mechanism, efficacy, side effects, and cost — matters for choosing the right fit.

The basic mechanisms

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which slows gastric emptying, increases insulin secretion in response to meals, and suppresses appetite. It's marketed as Ozempic (approved for Type 2 diabetes) and Wegovy (approved for chronic weight management).

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In addition to the GLP-1 effects, it also activates GIP receptors, which adds another layer of appetite and metabolic regulation. It's marketed as Mounjaro (diabetes) and Zepbound (weight management).

Efficacy data

In head-to-head and comparable-trial data, tirzepatide has produced greater weight loss on average. The SURPASS and SURMOUNT trials showed average weight reductions of 20-22% on tirzepatide at maximum dose, compared with 15-17% on semaglutide at maximum dose. That's a meaningful difference for many patients.

That said, individual response varies significantly, and some patients respond better to semaglutide than to tirzepatide. The averages mask a lot of individual variation.

Side effect profiles

Both medications have similar side effect patterns — gastrointestinal effects dominate, with nausea being most common, followed by constipation, diarrhea, and occasional vomiting. In clinical trials, tirzepatide had slightly higher rates of some side effects, which may reflect its greater potency. Most side effects ease as the body adjusts to each dose.

Dosing and titration

Both are weekly subcutaneous injections. Both start at a low dose and titrate up over several months. Semaglutide for weight loss typically tops out at 2.4 mg weekly. Tirzepatide tops out at 15 mg weekly. The slow titration is important for minimizing side effects — rushing the ramp-up usually backfires.

Cost and access

Both medications are expensive at list price (roughly $1,000-$1,300 per month without insurance coverage). Compounded versions have become available in some markets, though the FDA has begun limiting compounding now that branded supply has improved. Insurance coverage varies widely — diabetes indications are covered more consistently than weight management indications.

Which is better for women?

There's no clear "better for women" answer in the clinical data. Both have been studied in female-majority populations and both work. The choice often comes down to response (many patients try one first and switch if response is limited), tolerability (side effect burden on one versus the other), cost, and availability.

For women with significant perimenopausal or menopausal weight gain, the dual mechanism of tirzepatide has theoretical appeal because insulin sensitivity is a major factor in this pattern of weight change. The SURMOUNT trials showed strong results in populations that included many midlife women.

The practical decision

Most experienced prescribers will recommend starting with whichever is most available and affordable to you, evaluating response over two to three months, and switching if results are inadequate. The "right" medication is the one you can access consistently, tolerate well, and stay on long enough to see meaningful results.

Ready to get real answers about your health?

Join the Waitlist — Get 50% Off